Dr. Lin is a Professor of Radiation Oncology and a Physician-Scientist at The University of Texas MD Anderson Cancer Center. His practice focuses on thoracic malignancies. He leads clinical trials testing advanced radiation technologies or combining novel agents to enhance the current standard of care. His laboratory is also developing approaches that will enhance traditional cancer therapies. They are using drug screen approaches to identify drugs that could enhance both the cytotoxic effects but also immune stimulatory effects of radiation therapy. He is also interested in approaches to identify drivers of treatment resistance, and seek innovative strategies to counterbalance the resistance mechanisms. The focus is on clinical translation, taking potential drug candidates and testing them in preclinical studies to validate the utility of combining radiation sensitizers or immunomodulators with standard of care chemoradiotherapy or radiotherapy alone approaches for the management of lung or esophageal cancers. Applications are particularly pertinent in the metastatic setting, where ablative radiotherapy can act as immune adjuvants that can synergize with immunodulators to produce systemic anti-cancer immune responses.